HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
Status:
Active, not recruiting
Trial end date:
2022-03-25
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma patients are mostly diagnosed at locally advanced stage. Nowadays,
hepatic artery interventional therapy and/or systemic therapy are the main treatments options
for these patients. Our previous study showed that compared to than conventional
transcatheter arterial chemoembolization (TACE), hepatic arterial infusion chemotherapy
(HAIC) has better objective response, better safety profile, and increased resection rates.
The PD-1 inhibitors emerged in recent years have shown good momentum in the treatment of
hepatocellular carcinoma. The single-drug treatment on advanced hepatocellular carcinoma has
a tumor response rate of 17%, the disease control rate exceeds 60%, and the overall survival
time exceeds 12 months. And it has good tolerance and less adverse events. In studies of
other cancer, combined with traditional chemotherapy can further improve the efficacy of PD-1
inhibitors. Our study is a prospective phase II clinical study for patients with potentially
resectable locally advanced hepatocellular carcinoma (tumor confined to the liver with
invasion to branches of the portal vein or hepatic vein). Progressive survival (PFS) is the
primary end point of study. The OS and overall survival rate, RFS, ORR, DCR, conversion rate,
pathological response, and safety are the secondary endpoints. The efficacy and safety of
HAIC combined with PD-1 inhibitor in the treatment of potentially resectable locally advanced
hepatocellular carcinoma will be discussed.